biostudies-literatureUnknown10(59)Sanders AJActivated Leukocyte Cell Adhesion Molecule (ALCAM) has been linked to the progression of numerous human cancers, where it appears to play a complex role. The current study aims to further assess the importance of ALCAM in prostate cancer and the prognostic potential of serum ALCAM as a biomarker for prostate cancer progression. Here we demonstrate enhanced levels of tissue ALCAM are associated with metastasis. Additionally, elevated serum ALCAM is indicative of progression and poorer patient outlook, and demonstrates comparable prognostic ability to PSA in terms of metastasis and prostate cancer survival. ALCAM suppression enhanced proliferation and invasiveness in PC-3 cells and motility/migration in PC-3 and LNCaP cells. ALCAM suppressed PC-3 cells were generally less responsive to HGF aOncotarget6362-6377https://www.ebi.ac.uk/biostudies/studies/S-EPMC6824871biostudies-literatureImportance of activated leukocyte cell adhesion molecule (ALCAM) in prostate cancer progression and metastatic dissemination.PMC6824871Ye LCollins RJSanders AJRuge FMason MDJiang WGMorgan LDOwen SfalseImportance of activated leukocyte cell adhesion molecule (ALCAM) in prostate cancer progression and metastatic dissemination.Activated Leukocyte Cell Adhesion Molecule (ALCAM) has been linked to the progression of numerous human cancers, where it appears to play a complex role. The current study aims to further assess the importance of ALCAM in prostate cancer and the prognostic potential of serum ALCAM as a biomarker for prostate cancer progression. Here we demonstrate enhanced levels of tissue ALCAM are associated with metastasis. Additionally, elevated serum ALCAM is indicative of progression and poorer patient outlook, and demonstrates comparable prognostic ability to PSA in terms of metastasis and prostate cancer survival. ALCAM suppression enhanced proliferation and invasiveness in PC-3 cells and motility/migration in PC-3 and LNCaP cells. ALCAM suppressed PC-3 cells were generally less responsive to HGF a2019-01-01T00:00:00Z2019 Oct2025-04-19T03:15:27.605Z2019-11-13T08:03:16ZS-EPMC68248713169584410.18632/oncotarget.27279